Skip to content

Author

Mohammad Jawaıd Akhtar

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Unlocking the pharmacological potential of rhodanine derivatives: Drug design strategies and structure-activity relationships

Abstract The rhodanine core or 2-thioxothiazolidin-4-one, a five-membered heterocyclic ring system, has garnered significant interest in drug discovery, owing to its diverse biological activities. Derivatization of rhodamine has yielded many clinically useful therapeutic compounds for various ailments due to the presence of both nitrogen and sulfur heteroatoms within its ring system. Its broad-spectrum activities are facilitated by its two key electrophilic binding groups, ketone and thioketone, which enable interactions with various biological targets. Significant advances have been made toward its efficient synthetic strategies for drug discovery and development. This comprehensive review discusses rational design strategies for rhodanine-based heterocycles and their therapeutic potential as antibacterial, anti-diabetes, anti-Alzheimer’s, anticancer, anthelmintic, anti-obesity, and against COVID-19. The article also sheds light on the synthetic strategies used to develop rhodamine derivatives and drug design supported with detailed structure-activity relationships (SAR). Further molecular docking providing mechanistic insights into their binding modes within receptors are also presented. These structural insights could help in further rational design of potent rhodamine derivatives as newer and safer therapeutic agents. Graphical AbstractCentral yellow molecular structure linked to various disease icons: anticancer, antibacterial, anti-Alzheimer, anti-COVID-19, antidiabetic, and anthelmintic.The diagram presents a central yellow molecular structure with elements like nitrogen (N), sulfur (S), and oxygen (O). It illustrates connections to diverse biological applications: anticancer, antibacterial, anti-Alzheimer, anti-COVID-19, antidiabetic & anti-obesity, and anthelmintic, represented by icons in surrounding circles. A curved green line labeled "Structure Activity Relationship" encircles the categories. Above, a labeled 'Drug Design' oval and precursor molecules R-NH2, ClCH2COOH, and CS2 are included, visually connecting the drug synthesis process and biological targets.

R. Nath, Lakshminarayan Das, Arka Chakraborty et al. · 0 citations
Review Open access Sep 2026

Rational drug design, synthetic and artificial intelligence approaches for bioactive heterocycles: advances and perspectives.

Heterocyclic scaffolds are vital to medicinal chemistry due to their versatility, diversity, and ability to target various biological molecules. This review covers advances in designing and synthesizing bioactive heterocycles, highlighting structure-based drug design (SBDD) and ligand-based drug design (LBDD) approaches with computational modeling and Artificial Intelligence (AI) to find potent, selective molecules with good Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) profiles. Case studies show the successful development of heterocyclic drugs for cancer, microbial infections, inflammation, viral infections, and Central Nervous System (CNS) disorders. Synthetic methods have evolved from classical electrophilic/nucleophilic reactions to modern techniques like multicomponent reactions, microwave synthesis, metal catalysis, and green chemistry, making frameworks more accessible. The review discusses Quantitative Structure-Activity Relationship (QSAR) studies for molecular optimization. Challenges like synthetic complexity and resistance remain, but emerging trends like machine learning, omics, and enzyme synthesis offer new opportunities. Ultimately, combining design principles and innovative methods can speed up drug discovery and enable sustainable, personalized therapies with heterocyclic pharmacophores.

Debajit Dewan, Bhupender Nehra, R. Nath et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.